These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27531416)

  • 61. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
    Bartels DJ; Sullivan JC; Zhang EZ; Tigges AM; Dorrian JL; De Meyer S; Takemoto D; Dondero E; Kwong AD; Picchio G; Kieffer TL
    J Virol; 2013 Feb; 87(3):1544-53. PubMed ID: 23152524
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
    Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
    Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].
    Stoll-Keller F; Fafi-Kremer S; Wolf P; Doffoël M; Baumert T
    Bull Acad Natl Med; 2008 Nov; 192(8):1657-67; discussion 1667-8. PubMed ID: 19445379
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
    J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Very late relapse of hepatitis C virus infection immediately after liver transplant.
    Erard-Poinsot D; Scholtès C; Billoud C; Zoulim F; Dumortier J
    Am J Transplant; 2018 Oct; 18(10):2587-2590. PubMed ID: 29878644
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.
    Gurusamy KS; Tsochatzis E; Toon CD; Davidson BR; Burroughs AK
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006573. PubMed ID: 24297303
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
    Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
    Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
    Ramirez S; Bukh J
    Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Defining Breadth of Hepatitis C Virus Neutralization.
    Kinchen VJ; Bailey JR
    Front Immunol; 2018; 9():1703. PubMed ID: 30116237
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
    Pihl AF; Feng S; Offersgaard A; Alzua GP; Augestad EH; Mathiesen CK; Jensen TB; Krarup H; Law M; Prentoe J; Christensen JP; Bukh J; Gottwein JM
    J Hepatol; 2022 May; 76(5):1051-1061. PubMed ID: 34990750
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
    Xiao F; Fofana I; Heydmann L; Barth H; Soulier E; Habersetzer F; Doffoël M; Bukh J; Patel AH; Zeisel MB; Baumert TF
    PLoS Pathog; 2014 May; 10(5):e1004128. PubMed ID: 24830295
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interferon-free regimens in the liver-transplant setting.
    Lens S; Gambato M; Londoño MC; Forns X
    Semin Liver Dis; 2014 Feb; 34(1):58-71. PubMed ID: 24782259
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.
    Zeisel MB; Crouchet E; Baumert TF; Schuster C
    Viruses; 2015 Nov; 7(11):5659-85. PubMed ID: 26540069
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Current management and perspectives for HCV recurrence after liver transplantation.
    Coilly A; Roche B; Samuel D
    Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hepatitis C-associated focal proliferative glomerulonephritis in an aviremic recipient of a hepatitis C-positive antibody donor liver.
    Bohorquez H; Velez JCQ; Lusco M; Scheuermann J; Cohen AJ
    Am J Transplant; 2021 Aug; 21(8):2895-2899. PubMed ID: 33721396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.